Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.37 |
| ▸ | PGR | P06401 | 15/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.35 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5507192 | 0.82 | NR3C1 (0.56) | NR3C1PGRNR3C2AR | |
| SCHEMBL10976658 | 0.66 | MAOB (0.51) | KCNH2 | |
| SCHEMBL10979583 | 0.65 | KCNH2 (0.56) | KCNH2DRD2DRD4DRD3 | |
| SCHEMBL7934955 | 0.64 | KCNH2 (0.48) | KCNH2DRD2DRD4DRD3 | |
| SCHEMBL5505411 | 0.62 | NR3C1 (0.62) | NR3C1PGRNR3C2AR | |
| SCHEMBL3744895 | 0.59 | KCNH2 (0.52) | HCRTR1HCRTR2KCNH2DRD2DRD4 | |
| SCHEMBL12970221 | 0.59 | KDM4E (0.58) | KCNH2DRD2DRD4DRD3 | |
| SCHEMBL10180627 | 0.58 | FFAR1 (0.55) | KCNH2 | |
| SCHEMBL3110653 | 0.57 | KCNH2 (0.54) | HCRTR1HCRTR2KCNH2DRD2DRD4 | |
| SCHEMBL10458644 | 0.57 | IDO1 (0.59) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | NR3C1 533/4885PGR 953/4885HCRTR1 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.